AtriCure (NASDAQ:ATRC – Get Free Report) and Autonomix Medical (NASDAQ:AMIX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk and earnings.
Profitability
This table compares AtriCure and Autonomix Medical’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
AtriCure | -8.70% | -8.12% | -6.21% |
Autonomix Medical | N/A | -542.11% | -236.92% |
Valuation and Earnings
This table compares AtriCure and Autonomix Medical”s top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
AtriCure | $399.24 million | 4.82 | -$30.44 million | ($0.83) | -47.59 |
Autonomix Medical | N/A | N/A | -$15.43 million | ($16.07) | -0.20 |
Insider and Institutional Ownership
99.1% of AtriCure shares are held by institutional investors. Comparatively, 10.8% of Autonomix Medical shares are held by institutional investors. 3.2% of AtriCure shares are held by insiders. Comparatively, 32.4% of Autonomix Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of current ratings and price targets for AtriCure and Autonomix Medical, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
AtriCure | 0 | 0 | 8 | 0 | 3.00 |
Autonomix Medical | 0 | 0 | 1 | 0 | 3.00 |
AtriCure presently has a consensus target price of $43.38, suggesting a potential upside of 9.81%. Autonomix Medical has a consensus target price of $28.00, suggesting a potential upside of 772.27%. Given Autonomix Medical’s higher probable upside, analysts clearly believe Autonomix Medical is more favorable than AtriCure.
Summary
AtriCure beats Autonomix Medical on 6 of the 11 factors compared between the two stocks.
About AtriCure
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
About Autonomix Medical
Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.